Clinical trials: Squamous-Cell Lung Cancer
Lung Cancer
Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT00960999
- Testing
- Single-fraction stereotactic body radiation therapy (SBRT), Multiple-fraction stereotactic body radiation therapy (SBRT)
- Where
- 38 sites in United States, Canada
- Volunteers
- 94 people
- Sponsor
- Radiation Therapy Oncology Group
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC).
- Conditions
- Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT04310007
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 611 sites in United States
- Volunteers
- 117 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Breast Cancer
Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871
This research trial studies deoxyribonucleic acid (DNA) in blood samples from Caucasian and African-American cancer patients who received docetaxel on clinical trial CLB-9871.
- Conditions
- Bladder Cancer, Breast Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT01015963
- Testing
- laboratory biomarker analysis
- Volunteers
- 69 people
- Sponsor
- Alliance for Clinical Trials in Oncology
NSCLC
Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC
Anlotinib which has shown an affirmatory efficacy in ALTER0303 controlled trial as a 3rd-line treatment on advanced NSCLC is a tyrosine kinase inhibitor with a favorable safety profile in phase I trial which mainly targets…
- Trial name
- ALTER-L013 (NCT03799601)
- Testing
- Anlotinib, Docetaxel, Carboplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Tongji Hospital
Non-squamous Non-small Cell Lung Cancer
Paclitaxel-bevacizumab in Advanced Lung Cancer
The study objective is to evaluate the efficacy of paclitaxel-bevacizumab comparing to docetaxel. Docetaxel is a standard treatment of 2nd or 3rd line in lung cancer.
- Trial name
- Ultimate (NCT01763671)
- Testing
- Docetaxel, Paclitaxel, Bevacizumab
- Where
- 55 sites in France
- Volunteers
- 166 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
Activity of patritumab deruxtecan (U3-1402; HER3-DXd) has been shown in a phase I/II study in patients with HER3 expressing breast cancer as well as in a phase I study in patients with EGFR TKI refractory EGFR mutation positive…
- Conditions
- Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, EGFR Gene Mutation
- Trial name
- NCT06222489
- Testing
- 89Zr-Patritumab deruxtecan
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- The Netherlands Cancer Institute
Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer
A Study of ZW251 in Participants With Advanced Solid Tumors
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell…
- Conditions
- Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
- Trial name
- NCT07164313
- Testing
- ZW251
- Where
- 25 sites in United States, Ireland and 4 more
- Volunteers
- 140 people
- Sponsor
- Zymeworks BC Inc.
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard chemotherapy regimens in treating patients with solid tumors that have spread to other…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT02495896
- Testing
- Cisplatin, Docetaxel, Gemcitabine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Southern California
Solid Tumor, Colorectal Cancer
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
This is a phase 1 multi-center, open-label study evaluating IBI3028 Treatment in participants with locally advanced, unresectable, or metastatic solid tumors
- Conditions
- Solid Tumor, Colorectal Cancer, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07589205
- Testing
- Drug: IBI3028
- Where
- China
- Volunteers
- 493 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Carcinoma, Non-Small-Cell Lung
Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative
This is a single arm, multi-center clinical trial. Target population is advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients with Programmed Cell Death Ligand 1 (PD-L1) negative, aiming to evaluate the…
- Trial name
- ACHELOUS (NCT06001151)
- Testing
- Cadonilimab, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Qian Chu
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Epithelial Ovarian Cancer, Triple Negative Breast Cancer
A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
Study LCB-1801-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), first-in-human clinical study of NI-1801 in patients with advanced, metastatic, or recurrent solid malignancies expressing mesothelin…
- Conditions
- Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, Pancreatic Adenocarcinoma (ductal Adenocarcinoma)
- Trial name
- NCT05403554
- Testing
- Biological NI-1801, NI-1801 in combination with anti-PD1 (Pembrolizumab), NI-1801 in combination with paclitaxel
- Where
- 7 sites in France, Italy
- Volunteers
- 70 people
- Sponsor
- Light Chain Bioscience - Novimmune SA
Solid Tumors, Metastatic Melanoma
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of single agent lomvastomig (RO7121661), an anti PD-1 (programmed death-1) and TIM-3 (T-cell immunoglobulin and mucin domain 3)…
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
- Trial name
- NCT03708328
- Testing
- Lomvastomig
- Where
- 17 sites in United States, Denmark and 4 more
- Volunteers
- 134 people
- Sponsor
- Hoffmann-La Roche
Non-small-cell Lung Cancer
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
- Trial name
- NCT01138163
- Where
- 53 sites in United States, Georgia and 3 more
- Volunteers
- 121 people
- Sponsor
- Peregrine Pharmaceuticals
NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification
Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer
Microlyvaq™ is a first-line, non-randomized, two-arm clinical trial in advanced non-small cell lung cancer (NSCLC). In both arms, patients receive a personalized multi-epitope vaccine (Microlyvaq™) on top of standard-of-care…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification, Non-Squamous Non Small Cell Lung Cancer
- Trial name
- Microlyvaq™ (NCT07285434)
- Testing
- Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic)
- Where
- Greece
- Volunteers
- 90 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
This 2 arm study will assess the efficacy and safety of Tarceva plus gemcitabine, compared with gemcitabine alone, in the treatment of chemotherapy-naive patients with advanced non-small cell lung cancer.
- Trial name
- NCT00518011
- Testing
- Erlotinib, Gemcitabine
- Where
- 14 sites in Australia
- Volunteers
- 17 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00030771
- Testing
- Chemotherapy, Radiotherapy, Surgery
- Where
- 25 sites in Germany, Serbia and 1 more
- Volunteers
- 232 people
- Sponsor
- Swiss Cancer Institute
Non-squamous Non-small Cell Lung Cancer
A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus docetaxel and zoledronic versus docetaxel and zoledronic alone as second line treatment for advanced non-squamous non-small cell…
- Trial name
- NCT03127319
- Testing
- apatinib docetaxel zoledronic, docetaxel zoledronic
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital of Hebei University
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Non-squamous Non-small Cell Lung Cancer
SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined bevacizumab versus Sacituzumab Tirumotecan in the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer
- Trial name
- NCT07895992
- Testing
- SHR-A2009 + bevacizumab, Sacituzumab Tirumotecan
- Where
- China
- Volunteers
- 490 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.